NMRD - Nemaura Medical Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.27
+0.18 (+5.83%)
At close: 4:00PM EDT

3.15 -0.12 (-3.67%)
After hours: 6:29PM EDT

Stock chart is not supported by your current browser
Previous Close3.09
Open3.18
Bid3.11 x 1100
Ask3.49 x 1800
Day's Range3.00 - 3.33
52 Week Range2.05 - 6.80
Volume257,916
Avg. Volume135,157
Market Cap670.35M
Beta-2.43
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire11 hours ago

    Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar

    Nemaura Medical Inc., a medical technology company developing sugarBEAT ® as a non-invasive affordable and flexible Continuous Glucose Monitor for use by persons with diabetes and pre-diabetics, today ...

  • Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday
    Motley Fool5 days ago

    Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday

    The clinical-stage upstart is making progress in advancing a new type of glucose monitor to market.

  • GlobeNewswire6 days ago

    Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial

    9,371 data points were analysed in total, consisting of 4,630 and 4,741 paired data points analysed using 1-point and 2-point calibration respectively. The MARD (Mean Absolute Relative Deviation, @ 30%/30mg/dL) for the 1-point calibration was 12.19% (80% of all data), and for the 2-point calibration the MARD was 10.65% (88% of all data)). Continuous Glucose Monitoring (CGM) is estimated to have a global total addressable market worth $82Bn.

  • GlobeNewswirelast month

    Nemaura Medical Inc. Reports First Quarter 2018 Financial Results

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive glucose trending device for use by persons with diabetes and pre-diabetics today reported financial results for the first quarter ended June 30, 2018. • With its approved contract manufacturers, Nemaura commenced manufacturing scale-up in preparation for anticipated launch in the United Kingdom in the coming months. Dr Faz Chowdhury, CEO of Nemaura Medical commented “we have maintained our well capitalised financial position whilst incurring significant additional costs from commencing FDA clinical trials and scaling up our systems in readiness for anticipated UK commercial launch of sugarBEAT® later this year.

  • GlobeNewswire2 months ago

    Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study

    The interim results evaluated data from 25 patients, split approximately equally between Type I and Type II diabetics, each wearing sugarBEAT whilst going about their daily home/work routine for 1 or 2 non-consecutive days, for a total of 36 patient days. The results analysed 121 matched pair points between the BGM and sugarBEAT®, and indicated 84.3% of the data points had an overall MARD (Mean absolute relative deviation) of 10.63%, and an overall nominal MARD of 16.3% (compared with 14.8%, 16.3% and 18% for Eversense, Dexcom G5 and Abbott Libre Pro respectively*).

  • Business Wire2 months ago

    Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month, also manufactured in the UK, in preparation for the anticipated sugarBEAT® product launch in the coming months. SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals, and is expected to launch initially in the United Kingdom, upon CE Mark approval.

  • Business Wire3 months ago

    Nemaura Medical Inc. Reports Full Year Financial Results

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced financial results for the fiscal year ended March 31, 2018. Entered into a definitive collaboration agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA).

  • Business Wire4 months ago

    Nemaura Medical Signs Joint Collaboration Agreement for European Commercialization

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has entered in to a definitive joint Collaboration Agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA). “We are pleased to extend our relationship with DBE and believe their expertise will play an important role in the commercialization of sugarBEAT®.” said Dr. Faz Chowdhury, Chairman and CEO of Nemaura. DBE was founded by Dr. Dallas Burston (MBBS), a pharmaceutical marketing entrepreneur specializing in selling breakthrough medical products into European markets.

  • Business Wire4 months ago

    Nemaura Medical to Present at the UBS Global Healthcare Conference

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Chief Business Officer, Bashir Timol, will be presenting at the UBS Global Healthcare Conference, being held May 21-23, 2018 in New York. Nemaura Medical Inc. (NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes.

  • Business Wire5 months ago

    Nemaura Medical Appoints Bashir Timol Chief Business Officer

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, current Director of Strategy & Corporate Development, has been named Chief Business Officer, effective immediately.

  • Business Wire6 months ago

    Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has appointed The Ruth Group , a leading healthcare-focused strategic communications firm, to lead its investor and public relations initiatives in the United States and help build awareness of the Company’s ...

  • Business Wire6 months ago

    Nemaura Medical to Ring the Nasdaq Closing Bell

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, Director of Strategy and Corporate Development, will ring the closing bell of the Nasdaq Stock Market on Tuesday, March 6, 2018 at 4:00 pm ET.

  • Business Wire7 months ago

    Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has commenced expansion into new manufacturing facilities, enabling large scale production of its proprietary sensor technology.

  • Business Wire7 months ago

    Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today reported financial results for the third quarter ended December 31, 2017.

  • Business Wire8 months ago

    Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today announced positive summary data for its sugarBEAT® European clinical trial program.

  • Business Wire8 months ago

    Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive continuous glucose monitoring system for adjunctive use by persons with diabetes, today announced that its shares of common stock were approved for listing on the NASDAQ Capital Market.

  • Business Wire9 months ago

    Nemaura Announces Completion of SugarBEAT® European Clinical Trial Programme and Positive Interim Results

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® disposable adhesive skin-patch as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes, today announced the completion of its sugarBEAT® European clinical trial programme and positive interim accuracy data.

  • Business Wire9 months ago

    Nemaura Announces Successful SugarBEAT® Interim Precision Study Results

    Nemaura Medical Inc. , a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free glucose monitoring system, today announced sugarBEAT® interim precision data results as part of its ongoing European clinical trial programme.

  • Business Wire11 months ago

    Nemaura Medical Inc. Reports Second Quarter 2017 Financial Results

    Nemaura Medical Inc. , a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes, recently reported financial results for the second quarter ended September 30, 2017.

  • Business Wirelast year

    WallStreet Research™ Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc.

    WallStreet Research™ , a top-ranked independent research firm with a history spanning over three decades, today announced that it has initiated Corporate Profile coverage on Nemaura Medical, Inc.

  • Business Wirelast year

    Nemaura Announces Successful Interim Results for SugarBEAT® European Clinical Trials

    Nemaura Medical Inc. , a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free glucose monitoring system today announced interim clinical trial results for the sugarBEAT® European clinical trial programme.